SOUTH SAN FRANCISCO, Calif., June 23 /PRNewswire/ -- diaDexus, Inc. today announced the release of a supplement to The American Journal of Cardiology, Vol. 101, No 12A June 16, 2008 that includes an expert consensus panel recommendation to include testing for lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory marker, as an adjunct to traditional cardiovascular disease (CVD) risk assessment. These recommendations are consistent with and build on the Adult Treatment Panel III guidelines (ATP III) for the use of inflammatory markers in patients at moderate to high CVD risk to improve identification of those at even higher risk for heart attack and stroke who would benefit from proven therapeutic and lifestyle treatments to prevent these cardiovascular events.
The six paper supplement entitled "Advances in the Detection of Rupture- Prone Plaque: The Role of Lipoprotein-Associated Phospholipase A2 in Cardiovascular Risk Assessment" was authored by a consensus panel of experts in the fields of cardiology, neurology and laboratory medicine. The panel was formed to review the rapidly emerging literature on Lp-PLA2, an enzyme implicated in the formation of rupture prone plaque.
Peter H. Jones, MD, Associate Professor of Medicine and Co-Director,
Baylor Lipid and Atherosclerosis Clinic, Baylor College of Medicine,
Houston, Texas and co-author of the summary paper entitled "Consensus Panel
Recommendation for Incorporating Lipoprotein Associated Phospholipase A2
Testing into Cardiovascular Disease Risk Assessment Guidelines" comments,
"As a highly specific biomarker for vascular inflammation, Lp-PLA2 can
identify persons who are at increased risk for heart attack and/or stroke.
Elevated Lp- PLA2 levels should prompt consideration of increasing the
cardiovascular risk category from moderate to high or high to very high
risk, directing initiation or intensification of statin therapy to reduce
LDL-cholesterol to prevent heart a
|SOURCE diaDexus, Inc.|
Copyright©2008 PR Newswire.
All rights reserved